ERECTILE DYSFUNCTION
A growing global health concern with substantial commercial potential
Erectile Dysfunction affects more than 300million men globally, with prevalence increasing due to ageing populations, lifestyle factors, and comorbidities such as diabetes and cardiovascular disease.
Global Market Overview:
-Global ED market (prescription drugs): USD 5.3 billion (2025)
-Expected CAGR: 7.6% through 2030
-Dominated by oral PDE5 inhibitors (e.g. Tadalafil, Sildenafil)
-Growing interest in OTC and alternative formats (e.g. gummies, fast-dissolving strips)
Unmet Needs:
-Faster onset of action
-Reduced side effects
-Improved patient adherence
-Novel delivery formats with less stigma
Eve’s proprietary solubility platform targets reformulated Tadalafil in new delivery formats - starting with softgels and exploring OTC-compliant alternatives for specific markets.
Global Market Overview:
-Global ED market (prescription drugs): USD 5.3 billion (2025)
-Expected CAGR: 7.6% through 2030
-Dominated by oral PDE5 inhibitors (e.g. Tadalafil, Sildenafil)
-Growing interest in OTC and alternative formats (e.g. gummies, fast-dissolving strips)
Unmet Needs:
-Faster onset of action
-Reduced side effects
-Improved patient adherence
-Novel delivery formats with less stigma
Eve’s proprietary solubility platform targets reformulated Tadalafil in new delivery formats - starting with softgels and exploring OTC-compliant alternatives for specific markets.